Trials / Completed
CompletedNCT01535495
Propranolol for Diabetic Retinopathy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- University of Wisconsin, Madison · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is investigating if the oral beta antagonist propranolol can induce regression of retinal neovascularization associated with proliferative diabetic retinopathy.
Detailed description
Oral propranolol 120mg daily will be given to 10 patients with proliferative diabetic retinopathy over a 12 week period to evaluate the effect on retinal neovascularization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Propranolol | Propranolol XL 120mg by mouth once daily |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2012-02-17
- Last updated
- 2017-03-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01535495. Inclusion in this directory is not an endorsement.